Sanofi looking to hire Alstom’s chief executive
pharmafile | March 6, 2014 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Sanofi, alstom, kron
Sanofi is proposing to replace Lord Douro at the French firm with Patrick Kron as its new independent director.
Kron (pictured) has been the chief executive of power generation and multinational conglomerate firm Alstom since the beginning of 2003, and chairman and chief executive of the company since March that year.
Kron is a graduate of École polytechnique and the Paris École des mines. He started his career in the French Ministry of Industry where he served from 1979 until 1984. He then joined the Pechiney group where from 1984 until 1988 he held operational responsibilities in one of the group’s factories in Greece.
From 1988 to 1993 he occupied several positions within Pechiney, first managing a group of activities in the processing of aluminium and eventually as president of its electrometallurgy division.
In 1993 he became a member of the executive committee of the Pechiney group and was appointed chairman of the board of the Carbone Lorraine Company, a position he held until 1997.
From 1995 to 1997 he ran the Food and Health Care Packaging Sector of Pechiney and the position of chief operating officer of the American National Can Company in Chicago (US). From 1998 to 2002, Patrick Kron was chief executive of Imerys before joining Alstom in 2002.
This appointment if board-approved by Sanofi would then see its director board consist of 16 of the following members: Serge Weinberg – chairman, Christopher Viehbacher – chief executive, Laurent Attal, Uwe Bicker, Robert Castaigne, Thierry Desmarest, Jean-René Fourtou, Claudie Haigneré, Patrick Kron, Igor Landau, Fabienne Lecorvaisier, Suet-Fern Lee, Christian Mulliez, Carole Piwnica, Klaus Pohle, Gérard Van Kemmel.
Related Content
Sanofi and Regeneron’s Dupixent receives CHMP recommendation for chronic spontaneous urticaria
Sanofi and Regeneron have received a positive opinion from the European Medicines Agency’s (EMA) Committee …
Sanofi’s treatment granted orphan designation for rare chronic inflammatory condition
The European Medicines Agency has granted orphan designation to Sanofi’s investigational Bruton’s tyrosine kinase (BTK) …
Sanofi completes acquisition of Vigil Neuroscience to early neurology pipeline
Sanofi has announced that it has finalised its acquisition of Vigil Neuroscience, a US-based biotechnology …
